In­cyte gears up to face FDA once again with more Zynyz da­ta in rare anal can­cer

BARCELONA — In­cyte said it has pos­i­tive late-stage re­sults for its PD-1 drug Zynyz in cer­tain pa­tients with squa­mous cell car­ci­no­ma, three years af­ter the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER